Key clinical point: Adding lenalidomide to R-CHOP did not improve progression-free or overall survival in patients with newly diagnosed ABC-type diffuse large B-cell lymphoma (DLBCL).
Major finding: The median progression-free survival was not reached in either trial arm.
Study details: A randomized, phase 3 trial comparing R-CHOP, with or without lenalidomide, in 570 patients with DLBCL.
Disclosures: The ROBUST study was funded by Celgene. Dr. Vitolo reported consulting and speaker’s bureau fees and research funding from the company.
Vitolo U et al. 15-ICML, Abstract 005.